US 12,285,455 B2
Controlled-release and stratified cyclodextrin inclusion complex vehicles
Al Czap, Napa, CA (US)
Assigned to CZAP RESERACH AND DEVELOPMENT, LLC, Napa, CA (US)
Filed by CZAP RESEARCH AND DEVELOPMENT, LLC., Napa, CA (US)
Filed on Mar. 15, 2023, as Appl. No. 18/184,228.
Application 18/184,228 is a division of application No. 17/736,386, filed on May 4, 2022, granted, now 11,633,448.
Application 17/736,386 is a continuation of application No. 16/075,386, abandoned, previously published as PCT/US2017/016583, filed on Feb. 3, 2017.
Application 16/075,386 is a continuation of application No. 15/232,647, filed on Aug. 9, 2016, abandoned.
Application 16/075,386 is a continuation of application No. 15/285,264, filed on Oct. 4, 2016, abandoned.
Claims priority of provisional application 62/444,036, filed on Jan. 9, 2017.
Claims priority of provisional application 62/291,202, filed on Feb. 4, 2016.
Prior Publication US 2023/0405074 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/736 (2006.01); A61K 31/19 (2006.01); A61K 36/185 (2006.01); A61K 36/889 (2006.01); A61K 38/47 (2006.01); A61K 47/69 (2017.01); C08B 37/16 (2006.01); A61K 9/48 (2006.01)
CPC A61K 36/736 (2013.01) [A61K 31/19 (2013.01); A61K 36/185 (2013.01); A61K 36/889 (2013.01); A61K 38/47 (2013.01); A61K 47/6951 (2017.08); C08B 37/0015 (2013.01); A61K 9/48 (2013.01); C12Y 302/01 (2013.01); C12Y 302/01054 (2013.01)] 20 Claims
 
1. A method for treating pain and/or inflammation and ameliorating toxicity caused by acetaminophen usage and/or overdose, comprising orally administering to a human subject in need thereof an effective amount of a composition comprising:
a cyclodextrin having a cavity;
N-acetylcysteine and acetaminophen retained as stacked guest molecules within the cavity of the cyclodextrin, forming a cyclodextrin inclusion complex;
a pharmaceutically acceptable carrier for oral delivery of the cyclodextrin inclusion complex, wherein the N-acetylcysteine and acetaminophen are retained in the cyclodextrin inclusion complex within the pharmaceutically acceptable carrier; and, an enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin retaining the N-acetylcysteine and acetaminophen, wherein the cyclodextrin-degrading activity is activated on oral delivery of the composition to a human subject so as to release the N-acetylcysteine and acetaminophen from the cyclodextrin cavity.